Genentech Announces Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia

Article Link: Genentech Announces Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia

South San Francisco, CA — October 16, 2020 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of Venclexta (venetoclax) in…

Source: FDA New Drug Approvals